| Autor: |
Veiga AP; Laboratório de Alergia e Imunologia Clínica e Experimental, LIM-56, Rua Dr. Enéas de Carvalho, Brazil., Casseb J, Duarte AJ |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccine [Vaccine] 2006 Nov 30; Vol. 24 (49-50), pp. 7124-8. Date of Electronic Publication: 2006 Jul 18. |
| DOI: |
10.1016/j.vaccine.2006.06.079 |
| Abstrakt: |
HIV disease leads to defects in cell-mediated immunity, impairing the immune response to new and recall antigens. We studied 55 HIV 1-infected patients who received of recombinant DNA hepatitis B vaccine and 20 controls. The overall hepatitis B virus (HBV) seroconversion rate was 59%. The median CD4+ T cell count among responders was 452 cell/mm(3), higher than non-responders (359 cells/mm(3)). The HIV plasmaviral loads were higher in non-responders. We concluded that total T CD4 cell count, memory T CD4+ cells and lower plasma viral load among HIV-1-infected subjects treated with HAART could be used to predict the immune response to vaccination with hepatitis B vaccine. Thus, considering cost benefits, HVB vaccination should be preferentially provided to HIV-infected patients with T CD4 cells count over 450 cells/mm(3), preferentially whose under HIV replication controlled. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect